{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-083169","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.911422+00:00","generated_at":"2026-06-24T07:59:55.620296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Innoviva Q2 royalties up 7% to $111.7M; acquires Entasis, agrees to buy La Jolla","bullets":["Royalties increased 7% to $111.7M in Q2 2022 vs Q2 2021.","Income from operations decreased 14% to $82.6M due to Entasis consolidation.","Completed acquisition of remaining ~40% of Entasis for $2.20/share ($42M total).","Entered merger to acquire La Jolla Pharmaceutical for $6.23/share (~$149M enterprise value).","Sold 15% stake in Theravance Respiratory Co. to Royalty Pharma for ~$282M upfront plus potential $50M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-083169","json":"https://secwatch.observer/filing/0001104659-22-083169.json","markdown":"https://secwatch.observer/filing/0001104659-22-083169.md","text":"https://secwatch.observer/filing/0001104659-22-083169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922083169/0001104659-22-083169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922083169/tm2221883d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:59:55.620296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}